Trial · NCT00752726
Outcomes11
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 11 of 11
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Change From Baseline to Week 24 in Abdominal VAT Mass | Baseline to week 24 | This analysis was carried out for the observed ITT population, who had this post-baseline efficacy assessment. | kg | MEAN |
| SECONDARY | Change From Baseline to Week 12 in Abdominal VAT Mass | Baseline to week 12 | This analysis was carried out for the observed ITT population, who had this post-baseline efficacy assessment. | kg | MEAN |
| SECONDARY | Change From Baseline to Week 24 in Body Weight | Baseline to week 24 | This analysis was carried out for the observed ITT population, who had this post-baseline efficacy assessment. | kg | MEAN |
| SECONDARY | Change From Baseline to Week 24 in Total Fat Mass | Baseline to week 24 | This analysis was carried out for the observed ITT population, who had this post-baseline efficacy assessment. | kg | MEAN |
| SECONDARY | Change From Baseline to Week 24 in Percentage Body Fat | Baseline to week 24 | This analysis was carried out for the observed ITT population, who had this post-baseline efficacy assessment. | Percentage (%) body fat | MEAN |
| SECONDARY | Change From Baseline to Week 24 in Waist Circumference | Baseline to week 24 | This analysis was carried out for the observed ITT population, who had this post-baseline efficacy assessment. | cm | MEAN |
| SECONDARY | Change From Baseline to Week 24 in Percentage Liver Fat | Baseline to week 24 | ITT subset (participants who had this post-baseline efficacy assessment) from one study site was analysed for this parameter. | Percentage (%) IHL | MEAN |
| SECONDARY | Change From Baseline to Week 24 in Liver Fat | Baseline to week 24 | This analysis was carried out for the observed ITT population, who had this post-baseline efficacy assessment. | Hounsfield Units (HU) | MEAN |
| SECONDARY | Change From Baseline to Week 24 in Total Calories Expended for Physical Activity | Baseline to week 24 | This analysis was carried out for the observed ITT population, who had this post-baseline efficacy assessment. | Kilocalorie (kcal)/week | MEAN |
| SECONDARY | Change From Baseline to Week 24 in Quality of Life (QoL) Scores. | Baseline to week 24 | This analysis was carried out for the observed ITT population, i.e. ITT subjects who had this post-baseline efficacy assessment. | Score on a Scale | MEAN |
| SECONDARY | Selectivity Index at Week 24 | Baseline to week 24 | This analysis was carried out for the observed ITT population, who had this post-baseline efficacy assessment, only in Orlistat 60 mg group. This analysis was not carried out for placebo group. | Ratio | NUMBER |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00752726/outcomes